SCHEMBL4794291

SCHEMBL4794291

Cc1nc(N)c2ncn(CCCS(=O)(=O)c3ccc(Cl)cc3Cl)c2c1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90B1 P14625 1/20 0.37
KMT2A Q03164 1/20 0.37
HTT P42858 1/20 0.36
PDE8A O60658 1/20 0.34
SLC40A1 Q9NP59 1/20 0.34
ALDH1A1 P00352 3/20 0.34
DDR1 Q08345 2/20 0.34
POLB P06746 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
EDNRA P25101 1/20 0.33
YTHDC1 Q96MU7 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD11B1 P28845 1/20 0.32
P2RX7 Q99572 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5340121 0.97 HSP90B1 (0.37) HSP90B1KMT2AHTTPDE8ASLC40A1
SCHEMBL4791328 0.96 HSP90B1 (0.36) HSP90B1KMT2AHTTPDE8ASLC40A1
SCHEMBL4792027 0.85 HSP90B1 (0.38) HSP90B1KMT2AHTTSLC40A1ALDH1A1
SCHEMBL4877536 0.84 YTHDC1 (0.39) HSP90B1KMT2AHTTPDE8ASLC40A1
SCHEMBL4795274 0.83 HSP90B1 (0.40) HSP90B1KMT2ASLC40A1ALDH1A1DDR1
SCHEMBL4791886 0.82 HSP90B1 (0.37) HSP90B1KMT2AHTTSLC40A1ALDH1A1
SCHEMBL4793415 0.82 MAPK13 (0.34) KMT2AALDH1A1
SCHEMBL4791738 0.82 HSP90B1 (0.37) HSP90B1KMT2AHTTSLC40A1ALDH1A1
SCHEMBL4876618 0.81 YTHDC1 (0.38) HSP90B1HTTPDE8ASLC40A1POLB
SCHEMBL4792880 0.81 TLR7 (0.40) HSP90B1KMT2ASLC40A1ALDH1A1EDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513524-A4 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES CO (US) 2008-09-03 EP disclosed
US-7220758-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-22 US disclosed
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2006-11-09 US disclosed
US-7125890-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-24 US disclosed
EP-1513524-A2 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2005-03-16 EP disclosed
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed
US-6797718-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-28 US disclosed
US-20040010007-A1 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-01-15 US disclosed
WO-2003103584-A2 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES IL2, IL4, MYD88 HSP90B1 757/4885KMT2A 2883/4885HTT 4588/4885
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors IL2, IFNG, TSLP HSP90B1 403/4885KMT2A 3405/4885HTT 4440/4885
US-20040010007-A1 Ether substituted imidazopyridines IL2, IL4, MYD88 HSP90B1 757/4885KMT2A 2883/4885HTT 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.